1. Health

VX-770 - Potential Cure for Cystic Fibrosis Enters Second Phase 3 Trial

By August 9, 2009

People in the cystic fibrosis community are getting pretty excited about Vertex Pharmaceutical’s VX-770, a drug that could be the first to correct the genetic defect in some people with cystic fibrosis. One scientist even said that VX-770 is such a huge leap forward for CF research that its discovery is as big a deal as man walking on the moon. Whether VX-770 turns out to be the miracle drug many believe it will be remains to be seen, but the study results so far are very promising. VX-770 is currently being studied in two groups of CF patients with the G551D mutation -- A phase 3 trial in adults began in May, and a second phase 3 trial in 6-11 year olds began last week. Enrollment is still open for the second trial, which plans to recruit 30 children. If you would like your child to participate in the study, call the Vertex clinical trial hotline at (877) 634-8789 for more information.

Read more about VX-770 and other potential cystic fibrosis cures on the horizon.

- - - - - - - - - - - - - - - - -
Stay up to date:
Subscribe to the weekly CF newsletter.
Follow me on Twitter
- - - - - - - - - - - - - - - - -

Comments are closed for this post.
Leave a Comment

Line and paragraph breaks are automatic. Some HTML allowed: <a href="" title="">, <b>, <i>, <strike>

©2014 About.com. All rights reserved.

We comply with the HONcode standard
for trustworthy health
information: verify here.